Car Modification

ONK Therapeutics Presents Promising In-Vivo Knowledge of its Optimized Affinity CD38 CAR-NK Candidate, Being Developed for the Remedy of A number of Myeloma


Information and analysis earlier than you hear about it on CNBC and others. Declare your 1-week free trial to StreetInsider Premium right here.


  • First in-vivo knowledge for ONKT102, a totally human, optimized affinity CD38 CAR-NK cell remedy
  • Knowledge confirmed potent anti-tumor exercise in-vitro and in-vivo of cord-derived ONKT102 in a CD38 optimistic tumor mannequin of a number of myeloma
  • Poster offered on the Worldwide Myeloma Society 2022, 25-27 August 2022, Los Angeles, USA by CSO Prof. Michael O’Dwyer

GALWAY, Eire & SAN DIEGO–(BUSINESS WIRE)–
ONK Therapeutics, an revolutionary firm devoted to growing optimally engineered pure killer (NK) cell therapies to remedy sufferers with most cancers, at the moment introduced the primary in-vivo knowledge for ONKT102, a totally human, optimized affinity CD38 CAR-NK cell remedy.

The optimistic knowledge, offered in a poster on the Worldwide Myeloma Society late on Friday 26 August by ONK Therapeutics CSO Prof. Michael O’Dwyer confirmed potent anti-tumor exercise for ONKT102 in-vitro and in-vivo in a CD38 optimistic MM.1S-LUC tumor mannequin of a number of myeloma.

ONK Therapeutics is growing a pipeline of off-the-shelf, optimally engineered pure killer (NK) cell therapies expressing a chimeric antigen receptor (CAR), additional modified to boost tumor homing, persistence and metabolism, and to beat exhaustion within the tumor microenvironment. At present it has 4 applications in pre-clinical improvement throughout hematological malignancies and strong tumors. ONKT102 is the corporate’s most superior program, and is being superior in direction of scientific improvement as a possible remedy for sufferers with relapsed or refractory a number of myeloma (MM).

CD38 is a longtime immunotherapeutic goal in MM. On this research, expanded wire blood (CB) derived NK cells first underwent CRISPR gene enhancing to knock out CD38 to stop fratricide, following which they have been genetically modified to precise the optimized affinity CD38 CAR, utilizing Tc Buster, a non-viral transposon strategy developed by BioTechne. The anti-tumor efficacy of the optimized CD38 CAR-NK cells was then evaluated in NOD scid gamma (NSG) mice inoculated with MM.1S-LUC cells. Mice underwent weekly bioluminescient imaging to observe tumor burden. The outcomes confirmed that CD38 CAR-NK cells considerably decreased tumor burden and improved survival versus management CB NK cells and automobile management.

Prof. Michael O’Dwyer, founder and CSO at ONK Therapeutics stated, “These outcomes counsel that non-virally engineered, optimized affinity CD38 CAR-NK CD38 KO cells have potent anti-tumor exercise in-vitro and in-vivo in a CD38 optimistic tumor mannequin.

“We’re inspired by these knowledge and future work at ONK Therapeutics goals to optimize the dose and schedule, verify the favorable security profile and potential useful immune modulatory results of our strategy, in addition to the additional advantage of gene-editing with CRISPR/Cas9 to knock out CISH to boost persistence.”

DETAILS OF THE POSTER PRESENTATION

Convention: Worldwide Myeloma Society 2022, 25-27 August 2022, Los Angeles, USA

Poster: P-018: CB derived, optimized affinity CD38 CAR-NK cells with CD38 KO present promising in-vivo exercise in a A number of Myeloma mannequin

Authors: S. Brophy, ONK Therapeutics et al

Timing: Friday 26 August, 19.30-20.30 (Pacific time)

Location: West Corridor A

View the poster HERE.

-ENDS-

About ONK Therapeutics – www.onktherapeutics.com

ONK Therapeutics is an revolutionary cell remedy firm devoted to growing the subsequent technology of optimally engineered, off-the-shelf, pure killer (NK) cell therapies. With a rising pre-clinical pipeline concentrating on each hematological malignancies and strong tumors, ONK is advancing a number of cell remedy candidates in direction of the clinic, together with its lead program, ONKT102, an optimized affinity CD38 CAR-NK product, meant for the remedy of sufferers with relapsed/ refractory a number of myeloma. Learn in regards to the pipeline right here.

The corporate’s optimally engineered NK cell remedy platform makes use of a collection of proprietary gene edits and cell modification methods to optimize cytotoxic potential, persistence and the metabolic well being of NK cells, whereas lowering the potential for his or her exhaustion within the tumor microenvironment. These embrace CISH knockout (KO); the expression of excessive affinity, membrane sure, TNF-related apoptosis-inducing ligand variants (TRAILv) concentrating on DR5 or DR4; and the deletion of inhibitory receptors, together with extracellular proteins for instance CD96, and Siglec-7. Learn in regards to the platform right here.

ONK Therapeutics is headquartered within the med-tech hub of Galway, Eire, with a wholly-owned US subsidiary, ONK Therapeutics, Inc. primarily based at JLabs @ San Diego. Shareholders embrace Acorn Bioventures, Cormorant Asset Administration, ALSHC (principally Seamus Mulligan), and Enterprise Eire.

Comply with us on Twitter @ONKTherapeutics and LinkedIn.

ONK Therapeutics Presents Promising In-Vivo Knowledge of its Optimized Affinity CD38 CAR-NK Candidate, Being Developed for the Remedy of A number of Myeloma

Worldwide

Sue Charles, Charles Consultants – +44 7968 726585 [email protected]

Eire

Ray Gordon, Gordon MRM – +353 87 2417373 [email protected]

Supply: ONK Therapeutics

Related Articles

Leave a Reply

Back to top button